AZN - AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
2024-05-29 08:06:00 ET
AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global biopharma sector, and its investors could potentially be wealthier too.
But that doesn't make it the right choice for everyone, so it's important to dive into the details of exactly what it's setting out to do. Let's start by putting this plan into context relative to where the business is today.
In 2023, the biopharmaceutical brought in $45.8 billion in revenue . And it has 182 therapies in its pipeline, many of which are devoted to expanding the approved indications for products already on the market. More than 120 of its programs in oncology, rare disease, and biologics are in mid- to late-stage clinical trials; its pipeline is gargantuan, and also mature overall.
For further details see:
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?